FAQ: ProPhase Labs Inc. (NASDAQ: PRPH) Sells Subsidiaries to Focus on Core Businesses

What did ProPhase Labs Inc. announce?

ProPhase Labs Inc. announced the closing of the sale of its wholly owned subsidiaries, Pharmaloz Manufacturing Inc. and Pharmaloz Real Estate Holdings Inc., to a private equity group based in Houston, Texas, for approximately $23.6 million.

Why is the sale of Pharmaloz significant for ProPhase Labs?

The sale significantly bolstered ProPhase’s balance sheet and liquidity by eliminating over $20 million in debt, payables, and other contingent liabilities, allowing the company to focus on its core businesses.

How does this transaction benefit ProPhase Labs?

The transaction better positions ProPhase to focus on its promising and high-value core businesses in biotech, genomics, and diagnostics, including the development of potential game-changer diagnostics and therapeutics in the fight against cancer.

What are ProPhase Labs’ core businesses?

ProPhase Labs is a next-generation biotech, genomics, and diagnostics company focusing on Whole Genome Sequencing solutions, developing diagnostics and therapeutics for cancer, and commercializing health and wellness solutions.

Where can I view the full press release about this transaction?

The full press release can be viewed at https://ibn.fm/KKdCD.

Who acquired Pharmaloz from ProPhase Labs?

Pharmaloz was acquired by a private equity group based in Houston, Texas.

What is the goal of ProPhase Labs?

ProPhase Labs aims to create a healthier world with bold action and the power of insight, revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions and developing potential game-changer diagnostics and therapeutics.

How does InvestorWire contribute to ProPhase Labs’ announcement?

InvestorWire is a specialized communications platform that provides advanced wire-grade press release syndication, helping ProPhase Labs reach a wide audience of investors, influencers, consumers, journalists, and the general public.